` RAP (Resapp Health Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

RAP
vs
S&P/ASX 300

Over the past 12 months, RAP has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's 10% growth.

Stocks Performance
RAP vs S&P/ASX 300

Loading
RAP
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
RAP vs S&P/ASX 300

Loading
RAP
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
RAP vs S&P/ASX 300

Loading
RAP
S&P/ASX 300
Add Stock

Competitors Performance
Resapp Health Ltd vs Peers

S&P/ASX 300
RAP
VEEV
PME
DOCS
2413
Add Stock

Resapp Health Ltd
Glance View

Market Cap
176.2m AUD
Industry
Health Care

ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The firm has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The firm has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. The company also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The firm has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.

RAP Intrinsic Value
Not Available
Back to Top